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Abstract
Background
Multimorbidity is increasingly common and is associated with adverse health outcomes,
highlighting the need to broaden the single-disease framework that dominates medical
research. We examined the role of midlife clinical characteristics, socioeconomic position,
and behavioural factors in the development of cardiometabolic multimorbidity (at least 2 of
diabetes, coronary heart disease, and stroke), along with how these factors modify risk of
mortality.
Methods and findings
Data on 8,270 men and women were drawn from the Whitehall II cohort study, with mean
follow-up of 23.7 years (1985 to 2017). Three sets of risk factors were assessed at age 50
years, each on a 5-point scale: clinical profile (hypertension, hypercholesterolemia, over-
weight/obesity, family history of cardiometabolic disease), occupational position, and beha-
vioural factors (smoking, alcohol consumption, diet, physical activity). The outcomes
examined were cardiometabolic disease (diabetes, coronary heart disease, stroke), cardio-
metabolic multimorbidity, and mortality. We used multi-state models to examine the role of
risk factors in 5 components of the cardiometabolic disease trajectory: from healthy state to
first cardiometabolic disease, from first cardiometabolic disease to cardiometabolic multi-
morbidity, from healthy state to death, from first cardiometabolic disease to death, and from
cardiometabolic multimorbidity to death. A total of 2,501 participants developed 1 of the 3
cardiometabolic diseases, 511 developed cardiometabolic multimorbidity, and 1,406 died.
When behavioural and clinical risk factors were considered individually, only smoking was
associated with all five transitions. In a model containing all 3 risk factor scales, midlife clini-
cal profile was the strongest predictor of first cardiometabolic disease (hazard ratio for the
least versus most favourable profile: 3.74; 95% CI: 3.14–4.45) among disease-free
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participants. Among participants with 1 cardiometabolic disease, adverse midlife socioeco-
nomic (1.54; 95% CI: 1.10–2.15) and behavioural factors (2.00; 95% CI: 1.40–2.85), but not
clinical characteristics, were associated with progression to cardiometabolic multimorbidity.
Only midlife behavioural factors predicted mortality among participants with cardiometabolic
disease (2.12; 95% CI: 1.41–3.18) or cardiometabolic multimorbidity (3.47; 95% CI: 1.81–
6.66). A limitation is that the study was not large enough to estimate transitions between
each disease and subsequent outcomes and between all possible pairs of diseases.
Conclusions
The importance of specific midlife factors in disease progression, from disease-free state to
single disease, multimorbidity, and death, varies depending on the disease stage. While
clinical risk factors at age 50 determine the risk of incident cardiometabolic disease in a dis-
ease-free population, midlife socioeconomic and behavioural factors are stronger predictors
of progression to multimorbidity and mortality in people with cardiometabolic disease.
Author summary
Why was this study done?
• The prevalence of cardiometabolic multimorbidity increases with age, and any combi-
nation of diabetes, stroke, and coronary heart disease is associated with multiplicative
mortality risk.
• Previous studies have examined either risk factors for multimorbidity or the manner in
which multimorbidity shapes adverse health outcomes. No previous study to our knowl-
edge has examined how socioeconomic, behavioural, and clinical risk factors shape the
development, progression, and outcome of cardiometabolic multimorbidity.
What did the researchers do and find?
• Data were collected on socioeconomic, behavioural, and clinical risk factors at age 50
years on 8,270 participants from the Whitehall II study, and the participants were fol-
lowed over a mean 23.7 years for incident cardiometabolic disease (diabetes, coronary
heart disease, or stroke), cardiometabolic multimorbidity (2 or more cardiometabolic
diseases), and mortality.
• Clinical risk factors (hypertension, overweight and obesity, high cholesterol, and family
history of diabetes or cardiovascular disease) were important predictors of first cardio-
metabolic disease. However, socioeconomic and behavioural factors (physical activity,
alcohol consumption, diet, and smoking) determined progression to multimorbidity,
and only behavioural risk factors predicted mortality among participants with cardio-
metabolic disease or cardiometabolic multimorbidity.
• When risk factors were considered individually, smoking was associated with acceler-
ated transitions in the trajectory from the development of a first cardiometabolic disease
to multimorbidity and death.
Multimorbidity and mortality
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What do these findings mean?
• By considering risk factors in the progression from a disease-free state to death, we
determined the changing influence of socioeconomic, behavioural, and clinical risk
factors.
• Our findings demonstrate that a simple focus on one point in the health trajectory of
individuals misses the changing role of risk factors in the development, progression,
and outcome of cardiometabolic multimorbidity, a major public health challenge
worldwide.
Introduction
Multimorbidity refers to the co-occurrence of multiple chronic conditions in the same person
[1], and is known to increase with age [2–11]. Multimorbidity is associated with poor quality
of life, higher healthcare costs, and greater risk of disability and mortality [11,12]; the effects of
multimorbidity on adverse outcomes for the patient and the healthcare system are greater than
might be expected from chronic conditions occurring on their own [11,13–15]. A recent study
on cardiometabolic multimorbidity, defined using diabetes, coronary heart disease (CHD),
and stroke, found each additional disease to double the risk of death [4].
Studies on risk factors for multimorbidity have shown the importance of clinical risk factors
[16,17], socioeconomic factors [3,8,16,18], and behavioural factors [16,19,20], but it remains
unclear whether these factors affect the risk of developing a first chronic condition or progres-
sion to multimorbidity. In addition, although prognostic studies show greater risk of adverse
outcomes in those with multimorbidity, the factors that modify this risk remain unknown. A
further limitation of previous research is the piecemeal approach, where studies examine the
risk factors for multimorbidity and the prognosis of multimorbidity in separate analyses, often
with cross-sectional data used to examine the former. Thus, the characteristics that adversely
affect temporal progression from a first chronic disease to multimorbidity and subsequent
mortality are unknown. The identification of such factors would pave the way for interven-
tions that target the specific factors associated with the incidence and prognosis of
multimorbidity.
In order to address some of these limitations, we examined the role of clinical, socioeco-
nomic, and behavioural factors at age 50 years in the transitions from a healthy state to first
cardiometabolic disease, cardiometabolic multimorbidity, and subsequent mortality using
data spanning 30 years. The main focus of our analyses was the relative importance of clusters
of clinical, social, and behavioural risk factors; however, we also examined the associations of
individual behavioural and clinical risk factors with transitions.
Methods
Study population
Participants were drawn from the Whitehall II study, an ongoing cohort study of 10,308 per-
sons (6,895 men and 3,413 women), aged 35–55 years at study recruitment in 1985 [21]. At
Multimorbidity and mortality
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baseline, participants responded to a questionnaire and underwent a structured clinical evalua-
tion consisting of measures of anthropometry, cardiovascular and metabolic risk factors, and
diseases. Follow-up clinical assessments have taken place approximately every 4–5 years (1991,
1997, 2002, 2007, 2012, and 2015), with every wave taking approximately 2 years to complete.
Informed, written consent from participants and research ethics approvals (University College
London [UCL] ethics committee) are renewed at each contact; the latest approval was by the
Joint UCL/UCLH Committee on the Ethics of Human Research (Committee Alpha), reference
number 85/0938.
Assessment of risk factors
We extracted data on risk factors at the clinical examination closest to age 50 years, allowing a
±5-year margin, to remove the effect of baseline age in our estimates. This was done by using
data from the first 4 waves of the study (in 1985, 1991, 1997, and 2002) when the age range of
participants was 35–55, 40–64, 45–69, and 50–74 years. Thus, follow-up started at age 50 for all
participants, and analyses were restricted to those free of cardiometabolic disease (diabetes,
CHD, stroke) at age 50. Three sets of risk factors were examined, each on a 5-point scale, with
0 denoting the lowest risk, and 4 the highest risk.
Clinical profile was assessed using 4 measures, with thresholds defined using World Health
Organization guidelines. Hypertension was defined as systolic blood pressure 140 mm Hg,
diastolic blood pressure 90 mm Hg, or use of antihypertensive medication. Blood pressure
was assessed as part of the clinical examination as the mean of 2 measurements taken using a
Hawksley random zero sphygmomanometer with the participant in the sitting position after 5
minutes of rest. Overweight/obesity was defined as BMI 25 kg/m2; weight was measured in
underwear to the nearest 0.1 kg on Soehnle electronic scales with digital readout (Leifheit, Nas-
sau, Germany), and height was measured in bare feet to the nearest 1 mm using a stadiometer
with the participant standing erect with the head in the Frankfurt plane. Hypercholesterolemia
was defined as total cholesterol 5 mmol/l. Venous blood samples were taken after at least 5
hours of fasting, and serum obtained after centrifugation was refrigerated at 4˚C and assayed
within 72 hours of the blood draw. Total cholesterol was measured using a Cobas Fara centrif-
ugal analyzer (Roche Diagnostics, Nutley, NJ). Finally, family history (parent or sibling) of dia-
betes and cardiovascular disease was reported as part of the study questionnaire.
The socioeconomic marker for the main analysis was occupational position, which in our
study is the British Civil Service grade of employment—a comprehensive measure that reflects
education, occupational status, and income, composed of a 5-level variable [21]. In sensitivity
analyses we replaced occupational position with education, measured as the highest qualifica-
tion on leaving full-time education (no academic qualifications, lower secondary school,
higher secondary school, university, higher degree).
Behavioural factors considered were smoking, alcohol consumption, fruit and vegetable
consumption, and physical activity. Each behaviour was scored as unhealthy (1 point) if rec-
ommended targets were not achieved and, in the case of dietary behaviour, to reflect previous
categorisation of this measure [22]; the scores were summed to yield an unhealthy behaviour
5-point scale. The criteria for classifying participants as not achieving recommended beha-
vioural targets were as follows: current smoking, alcohol abstention (<1 unit/week) or heavy
alcohol consumption (>21 alcohol units/week in men and>14 alcohol units/week in
women), poor diet (fruit and vegetable consumption < 1 serving/day), being physically inac-
tive (<2.5 hours/week of moderate or vigorous physical activity) [23].
Covariates included age, sex, race (white, non-white), marital status (single, non-single),
and birth cohort (4 categories:1935, 1936–1940, 1941–1945, >1945).
Multimorbidity and mortality
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Ascertainment of cardiometabolic diseases and multimorbidity
Incidence of cardiometabolic multimorbidity [4], defined as at least 2 of CHD, stroke, and dia-
betes, was based on data from the clinical assessments between 1985 and 2016 and linkage
(until 31 August 2017) to the national Hospital Episode Statistics (HES) database with in- and
outpatient data, undertaken using the National Health Service (NHS) identification number.
In the UK, the NHS provides most of the healthcare; private medical insurance is held by
around 12% of the population (1997 figures) [24] and is used mainly for elective surgery rather
than chronic conditions. The HES database contains the exact date of diagnosis (hospitalisa-
tion/outpatient visit), allowing greater precision in the time of follow-up.
Whitehall II ascertained non-fatal CHD based on 12-lead resting ECG recordings, coded
using the Minnesota system, and on self-reported CHD that was corroborated with informa-
tion from the general practitioner or manual retrieval of hospital records. The ascertainment
included non-fatal myocardial infarction, definite angina, reported coronary artery bypass
grafting, and percutaneous transluminal coronary angioplasty. HES ascertainment was based
on in- or outpatient hospital consultations with ICD-9 codes 410–414, ICD-10 codes I20–I25,
or procedures K40–K49, K50, K75, U19 (Office of Population Censuses and Surveys Classifica-
tion of Interventions and Procedures codes for all intra-hospital medical and surgical proce-
dures for treatment of CHD).
Stroke cases were defined using ICD-9 codes 430, 431, 434, or 436 or ICD-10 codes I60–I64
from HES records and self-reported stroke, which was validated against medical records [25].
Diagnosis of type 2 diabetes was based on the following diagnostic criteria: having fasting
glucose 7.0 mmol/l (126 mg/dl) or 2-hour plasma glucose 11.1 mmol/l (200 mg/dl),
reported physician-diagnosed diabetes, use of diabetes medication, or HES record of diabetes
(ICD-9 code 250 or ICD-10 code E11).
Mortality follow-up
Mortality data until 31 August 2017 were drawn from the British national mortality register
(NHS Central Register). The tracing exercise was carried out using the NHS identification
number of each participant.
Statistical analysis
To allow comparisons with other findings and demonstrate the value of our analytic approach,
we first used Cox regression to examine the association of risk factors (occupation, behavioural
factors, and clinical profile) with incidence of first cardiometabolic disease (any of the 3), mul-
timorbidity, and mortality. Participants were followed starting at age 50 years until the record
of death or 31 August 2017, whichever came first.
All risk factor scales were on a 5-point scale where they were first treated as categorical vari-
ables (0, 1, 2, 3, or 4, where 0 indicates no risk factors/lowest risk category and 4 indicates all 4
risk factors/highest risk category). As none of the associations showed evidence of departure
from linearity, we entered the risk factor scales as a continuous 5-level variable to assess the
impact of clustering of risk factors. The reported hazard corresponds to the increased risk of
the outcome (first cardiometabolic disease, multimorbidity, or mortality; separate analyses) in
those with the highest (score of 4, the maximum score) compared to the lowest risk (score on
scale = 0). The proportional hazard assumptions for Cox regression models, tested using
Schoenfeld residuals, were found not to be violated.
In subsequent analyses, we examined the role of the 3 risk factor scales (socioeconomic,
behavioural, and clinical) at age 50 in the temporal disease progression from being free of car-
diometabolic disease to first cardiometabolic disease, cardiometabolic multimorbidity, and
Multimorbidity and mortality
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death. These analyses were carried out using unidirectional multi-state models (MSMs) with
Markov proportional hazards [26,27]. These models are an extension of competing risks sur-
vival analysis, allowing simultaneous estimation of the role of risk factors (here socioeconomic,
behavioural, and clinical profile scales) in the transitions (for schematic representation see Fig
1) from (A) healthy to first cardiometabolic disease, (B) first cardiometabolic disease to cardio-
metabolic multimorbidity, (C) healthy state to death, (D) first cardiometabolic disease to
death, and (E) cardiometabolic multimorbidity to death. The focus on these 5 transitions
rather than all possible transitions in health states was pre-planned; an extract from our fund-
ing application can be found in S1 Protocol.
We also report the associations of the individual risk factors included in the behavioural
and clinical scales in both the Cox regression models and MSMs. In all the analyses, age was
used as the timescale, and analyses were additionally adjusted for sex, race, marital status, and
birth cohort (Model 1). The mutually adjusted models (Model 2) contained all covariates in
Model 1 and all risk factor scales (socioeconomic, behavioural, and clinical). Sex differences
were tested using an interaction term between the risk factor scale and sex for both the Cox
regression and the MSM analysis.
We repeated all the analyses with education replacing occupational position as a marker of
socioeconomic position, as education is a more widely available measure of socioeconomic cir-
cumstances in most studies. The MSMs were run using the “mstate” package of R software; all
other analyses used Stata version 14. A 2-sided p-value< 0.05 was considered statistically sig-
nificant. This study is reported as per STROBE guidelines (S1 Checklist).
Results
The analyses were based on 8,270 of the 10,308 participants recruited to the study in 1985
(flowchart in S1 Fig), followed over a mean 23.7 (SD = 5.9) years. As all risk factors were
drawn at around age 50 years, participants older than this at baseline, those who dropped out
of the study before reaching this age, and those with missing data on risk factors at age 50 were
excluded from the analysis (N = 1,581). Table 1 presents the sample characteristics at age 50 as
a function of cardiometabolic multimorbidity and mortality status at the end of follow-up;
these characteristics in relation to the 3 individual diseases considered in the analyses (diabe-
tes, CHD, and stroke) are shown in S1 Table.
A total of 2,501 (30.2%) of the 8,270 participants included in the analyses experienced 1 of
the 3 cardiometabolic diseases, 511 participants met the criteria of multimorbidity, and 1,406
participants died over the follow-up period, with the mean age (SD) at death being 70.0 (8.6)
years. Both first cardiometabolic disease (hazard ratio [HR]: 1.81; 95% CI: 1.61–2.03; mean
[SD] follow-up 10.8 [7.4] years) and cardiometabolic multimorbidity (HR: 2.36; 95% CI: 1.97–
2.81; mean [SD] follow-up 6.9 [5.8] years), treated as time-varying covariates in Cox regression
analysis adjusted for age, sex, race, marital status, and birth cohort, were associated with
increased risk of mortality over the follow-up period (S2 Table).
In Cox regression, all individual behavioural and clinical risk factors were associated with
first cardiometabolic disease (S3 Table). Overweight/obesity had the strongest association with
first cardiometabolic disease, and smoking the strongest association with both cardiometabolic
multimorbidity and mortality. Table 2 shows the gradient in the association between each risk
score and the outcomes, justifying the use of a linear scale to assess risk in those at highest
compared to lowest risk. All 3 risk scales (clinical, socioeconomic, and behavioural) at age 50
had a robust association with incidence of a first cardiometabolic disease, cardiometabolic
multimorbidity, and mortality in analysis using Cox regression (Table 2); men and women
were combined as there was no clear evidence of systematic sex differences (interaction terms
Multimorbidity and mortality
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in the footnotes of Table 2). For morbidity outcomes, the strongest associations were seen with
the clinical profile scale for both first cardiometabolic disease (HR: 3.74; 95% CI: 3.14–4.46)
and cardiometabolic multimorbidity (HR: 3.68; 95% CI: 2.49–5.43), with the magnitude of
these associations, which estimate excess risk in those with highest compared to lowest score
on the risk factor score, being very similar. The association of occupation and behavioural fac-
tors with incidence of multimorbidity was stronger than that with first cardiometabolic dis-
ease: HR of 2.43 versus 1.57 for the occupational scale and 3.02 versus 1.60 for the behavioural
scale.
Fig 1. Schematic representation of the transitions between start of follow-up (healthy), first cardiometabolic
disease, cardiometabolic multimorbidity, and mortality.
https://doi.org/10.1371/journal.pmed.1002571.g001
Table 1. Characteristics of the study population at age 50 as a function of multimorbidity and mortality status at the end of follow-up (N = 8,270).
Characteristic Cardiometabolic multimorbidity Mortality
No Yes p-Value No Yes p-Value
N 7,759 511 6,864 1,406
Age, mean (SD) 50.2 (2.4) 51.0 (2.3) <0.001 50.0 (2.3) 51.2 (2.5) <0.001
Male 67.0 68.9 0.38 67.7 64.2 0.01
Non-white 9.2 25.8 <0.001 9.9 11.7 0.05
Single 24.5 22.3 0.26 23.7 27.9 0.001
No academic qualification 10.3 15.3 <0.001 10.1 12.9 <0.001
Low occupational position (clerical/support staff) 18.7 29.8 <0.001 17.7 27.7 <0.001
Physically inactivea 50.1 55.4 0.02 50.0 52.5 0.09
Poor dietb 37.5 44.8 0.001 36.4 45.2 <0.001
Alcohol abstention or heavy alcohol consumptionc 36.8 42.9 0.006 36.5 40.5 0.005
Current smoker 14.9 24.7 <0.001 12.9 28.6 <0.001
Hypertensiond 20.3 30.3 <0.001 19.1 29.5 <0.001
Overweight/obesitye 47.5 61.6 <0.001 47.8 51.2 0.02
Total cholesterol  5 mmol/l 86.6 90.6 0.01 86.7 87.8 0.27
Family history of diabetes or CVD 17.9 19.4 0.41 18.4 16.4 0.09
Data are percentages unless otherwise indicated.
aCorresponds to <2.5 hours/week of moderate or vigorous physical activity (recommended level).
bCorresponds to fruit and vegetable consumption < 1 serving/day.
cHeavy alcohol consumption was defined as >14 units/week in women and >21 units/week in men, and alcohol abstention was defined as <1 unit/week.
dBlood pressure 140/90 mm Hg or use of antihypertensive medication.
eBMI 25 kg/m2.
CVD, cardiovascular disease.
https://doi.org/10.1371/journal.pmed.1002571.t001
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Table 2 also shows the associations of the risk factors with mortality using Cox regression.
Of the 3 risk factors, behavioural factors had the strongest association with mortality (HR of
Table 2. Cox regression to assess associations of occupation, behavioural factors, and clinical profile with cardio-
metabolic disease, multimorbidity, and mortality.
Risk factor N total First cardiometabolic
disease
Cardiometabolic
multimorbidity
Mortality
N events HR (95% CI) N events HR (95% CI) N events HR (95% CI)
Occupational
position
0 (high) 1,410 380 1.00 [Ref.] 53 1.00 [Ref.] 197 1.00 [Ref.]
1 1,695 448 1.05 (0.92,
1.21)
66 1.16 (0.81,
1.67)
234 1.11 (0.92,
1.35)
2 2,438 701 1.19 (1.05,
1.35)
152 1.82 (1.33,
2.50)
357 1.17 (0.98,
1.40)
3 1,122 380 1.39 (1.19,
1.61)
88 1.98 (1.37,
2.84)
229 1.55 (1.27,
1.91)
4 (low) 1,605 592 1.54 (1.32,
1.79)
152 2.38 (1.66,
3.41)
389 1.65 (1.35,
2.02)
Occupation scalea,b 8,270 2,501 1.57 (1.36,
1.81)
511 2.43 (1.75,
3.37)
1,406 1.68 (1.39,
2.03)
Behavioural factors
0 (healthiest) 1,587 452 1.00 [Ref.] 67 1.00 [Ref.] 189 1.00 [Ref.]
1 3,063 857 1.00 (0.89,
1.12)
161 1.26 (0.95,
1.68)
453 1.30 (1.09,
1.54)
2 2,433 772 1.17 (1.04,
1.31)
171 1.66 (1.24,
2.21)
460 1.69 (1.43,
2.01)
3 1,007 355 1.37 (1.19,
1.58)
94 2.23 (1.62,
3.07)
245 2.24 (1.85,
2.72)
4 (unhealthiest) 180 65 1.64 (1.26,
2.13)
18 3.09 (1.83,
5.22)
59 3.64 (2.71,
4.89)
Behavioural scalea,c 8,270 2,501 1.60 (1.37,
1.88)
511 3.02 (2.13,
4.29)
1,406 3.16 (2.57,
3.90)
Clinical profile
0 (healthiest) 490 91 1.00 [Ref.] 15 1.00 [Ref.] 65 1.00 [Ref.]
1 2,961 672 1.14 (0.92,
1.43)
124 1.20 (0.70,
2.05)
457 1.02 (0.79,
1.33)
2 3,201 1,051 1.78 (1.44,
2.20)
221 1.94 (1.15,
3.28)
550 1.16 (0.90,
1.50)
3 1,431 605 2.44 (1.95,
3.04)
138 2.67 (1.56,
4.55)
294 1.35 (1.03,
1.76)
4 (unhealthiest) 187 82 2.63 (1.95,
3.54)
13 2.07 (0.98,
4.36)
40 1.56 (1.05,
2.32)
Clinical profile
scalea,d
8,270 2,501 3.74 (3.14,
4.46)
511 3.68 (2.49,
5.43)
1,406 1.65 (1.30,
2.09)
aHR for highest versus lowest in the scale. Analysis adjusted for age, sex, race, marital status, and birth cohort.
bInteraction term for sex differences: first cardiometabolic disease, p = 0.002; multimorbidity, p = 0.25; mortality, p =
0.04.
cInteraction term for sex differences: first cardiometabolic disease, p = 0.25; multimorbidity, p = 0.34; mortality, p =
0.11.
dInteraction term for sex differences: first cardiometabolic disease, p = 0.16; multimorbidity, p = 0.35; mortality, p =
0.07.
HR, hazard ratio.
https://doi.org/10.1371/journal.pmed.1002571.t002
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3.16 in those with all adverse behaviours compared to those with none; 95% CI: 2.57–3.90),
although both occupation and clinical profile were also associated with mortality. As with first
cardiometabolic disease and multimorbidity, the linearity of associations underpins the use of
the risk scale to compare mortality risk in those with the highest compared to the lowest risk.
Mutual adjustment of risk factors (S4 Table) did not substantially alter associations with mor-
bidity or mortality.
Subsequent analyses estimated the role of risk factors in the transitions shown in Fig 1. We
first examined associations of individual behavioural and clinical risk factors with the transi-
tions, which showed smoking to be the only risk factor that was important for all 5 transitions
(Table 3). Subsequent analyses focused on risk factor scales; Table 4 shows the results of these
Table 3. Role of individual risk factors in transitionsa from a healthy state to first cardiometabolic disease, multimorbidity, and mortality.
Risk factorb Hazard ratio (95% CI) for transition
A (healthy to first
disease)
B (first disease to
multimorbidity)
C (healthy to
mortality)
D (first disease to
mortality)
E (multimorbidity to
mortality)
Behavioural factors
Physically inactivec 1.08 (1.00 1.17) 1.14 (0.95, 1.37) 1.08 (0.94, 1.24) 1.14 (0.92, 1.40) 1.07 (0.76, 1.51)
Poor dietd 1.09 (1.00, 1.18) 1.14 (0.96, 1.36) 1.31 (1.15, 1.50) 1.17 (0.95, 1.44) 1.79 (1.29, 2.48)
Alcohol abstention or heavy alcohol
consumptione
1.11 (1.03, 1.21) 1.30 (1.09, 1.56) 1.25 (1.09, 1.43) 1.17 (0.95, 1.45) 1.39 (1.00, 1.94)
Current smoker 1.43 (1.30, 1.59) 1.57 (1.28, 1.92) 2.44 (2.10, 2.84) 1.72 (1.36,2.16) 1.59 (1.12, 2.26)
Clinical profile
Hypertensionf 1.53 (1.40, 1.67) 1.02 (0.85, 1.24) 1.47 (1.26, 1.71) 1.30 (1.05, 1.61) 0.97 (0.69, 1.37)
Overweight/obesityg 1.70 (1.56, 1.84) 1.19 (1.00, 1.43) 1.15 (1.01, 1.31) 1.06 (0.86, 1.30) 0.85 (0.61, 1.18)
Total cholesterol  5 mmol/l 1.30 (1.14, 1.48) 1.08 (0.80, 1.46) 0.93 (0.76, 1.13) 0.87 (0.63, 1.22) 0.57 (0.35, 0.93)
Family history of diabetes or CVD 1.21 (1.09, 1.33) 0.94 (0.76, 1.18) 0.84 (0.70, 1.01) 0.98 (0.76, 1.27) 0.89 (0.58, 1.35)
aFor transitions see Fig 1.
bIndividual risk factors are dichotomous; reference group is composed of persons without the risk factor.
cCorresponds to <2.5 hours/week of moderate or vigorous physical activity (recommended level).
dCorresponds to fruit and vegetable consumption < 1 serving/day.
eHeavy alcohol consumption was defined as >14 units/week in women and >21 units/week in men, and alcohol abstention was defined as <1 unit/week.
fBlood pressure 140/90 mm Hg or use of antihypertensive medication.
gBMI 25 kg/m2.
CVD, cardiovascular disease.
https://doi.org/10.1371/journal.pmed.1002571.t003
Table 4. Role of occupation, behavioural factors, and clinical profile in transitionsa from a healthy state to first cardiometabolic disease, multimorbidity, and
mortality.
Transition N events/total Hazard ratio (95% CI)b for risk factor
Model 1 Model 2
Occupation Behavioural factors Clinical profile Occupation Behavioural factors Clinical profile
A (healthy to first disease) 2,501/8,270 1.57 (1.36, 1.81) 1.59 (1.35, 1.86) 3.81 (3.20, 4.53) 1.42 (1.23, 1.64) 1.44 (1.22, 1.69) 3.74 (3.14, 4.45)
B (first disease to multimorbidity) 511/2,501 1.77 (1.27, 2.47) 2.18 (1.54, 3.09) 1.28 (0.86, 1.91) 1.54 (1.10, 2.15) 2.00 (1.40, 2.85) 1.29 (0.86, 1.94)
C (healthy to mortality) 872/8,270 1.64 (1.29, 2.08) 3.08 (2.36, 4.02) 1.47 (1.09, 1.99) 1.33 (1.04, 1.69) 2.87 (2.19, 3.77) 1.42 (1.05, 1.93)
D (first disease to mortality) 383/2,501 1.18 (0.81, 1.70) 2.09 (1.40, 3.11) 1.38 (0.87, 2.19) 1.00 (0.69, 1.45) 2.12 (1.41, 3.18) 1.42 (0.89, 2.26)
E (multimorbidity to mortality) 151/511 2.30 (1.21, 4.39) 3.82 (2.01, 7.25) 0.64 (0.31, 1.34) 1.65 (0.86, 3.20) 3.47 (1.81, 6.66) 0.67 (0.32, 1.40)
Model 1: analysis adjusted for age, sex, race, marital status, and birth cohort. Model 2: Model 1 plus mutual adjustment for scales of occupation, behavioural factors, and
clinical profile.
aFor transitions see Fig 1.
bHazard ratio for lowest versus highest in scales of occupation, behavioural factors, and clinical profile.
https://doi.org/10.1371/journal.pmed.1002571.t004
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analyses, and when all 3 risk factor scales (Model 2) were considered simultaneously, clinical
profile had the strongest association (HR of 3.74 in those with all 4 risk factors compared to
none; 95% CI: 3.14–4.45) with the incidence of first disease (diabetes, CHD, or stroke) (transi-
tion A). However, in those with a first cardiometabolic disease, it was not associated with
increased risk of multimorbidity (transition B; HR: 1.29; 95% CI: 0.86–1.94). Both occupa-
tional disadvantage and adverse behavioural factors were associated with increased hazard of
multimorbidity in those with a first cardiometabolic disease (transition B). Within this frame-
work that modelled all transitions simultaneously, behavioural factors had the strongest associ-
ation with prognostic transitions, i.e., transitions leading to death. This was true for transitions
to death in participants without cardiometabolic diseases (transition C; HR: 2.87; 95% CI:
2.19–3.77), those with 1 cardiometabolic disease (transition D; HR: 2.12; 95% CI: 1.41–3.18),
and those with multimorbidity (transition E; HR: 3.47; 95% CI: 1.81–6.66; all estimates from
Model 2).
In sensitivity analyses, we examined the role of risk factor scales in transitions separately in
men and women (S5 Table). These results show small differences in the role of occupational
position but no differences for behavioural or clinical risk factor scales. In further analyses, we
used education rather than occupation as a marker of socioeconomic circumstances (S6
Table); these results were broadly consistent with our main findings.
Discussion
The emerging body of research on multimorbidity has assessed the role of risk factors for mul-
timorbidity [3,6,8,16–20] or examined the risk of mortality in those with multimorbidity [4].
In contrast, we examined the role of clinical, socioeconomic, and behavioural risk factors at
age 50 years in modifying transitions in health using MSMs, an approach that allows the
assessment of both etiological and prognostic factors within a single analytic framework. We
present 3 key findings. One, clinical parameters were the strongest predictors of the incidence
of a first cardiometabolic disease, but they played a more modest role in progression from a
single disease to cardiometabolic multimorbidity or risk of mortality in those with cardiometa-
bolic multimorbidity. Two, midlife socioeconomic and behavioural factors were found to be
important predictors of multimorbidity in those with existing cardiometabolic disease. Three,
midlife behavioural factors were important predictors of mortality in those free of cardiometa-
bolic diseases, those with 1 cardiometabolic disease, and those with cardiometabolic multimor-
bidity: the respective HRs for those with the worst compared to the best behavioural profile all
exceed 2, indicating their considerable impact on mortality risk.
The objective of our analysis was to identify how known clinical, socioeconomic, and beha-
vioural risk factors shape the course of cardiometabolic disease. The precise pathophysiological
mechanisms underlying the association of risk factors with disease incidence and prognosis
were not examined. Each of our 3 main findings has implications for prevention and care of
persons with cardiometabolic disease. The importance of clinical parameters, individually and
when considered as a scale for their combined impact, for the incidence of a first cardiometa-
bolic disease suggests that basic clinical factors are not yet being targeted sufficiently in pri-
mary prevention. The decline in deaths from cardiovascular disease in high-income countries
is attributed in large part to such prevention strategies [28,29]. However, our data show large
variation in clinical factors and that an adverse clinical profile is associated with a 3.7-fold
greater hazard of a first cardiometabolic disease in fully adjusted analyses. These findings
should encourage further efforts to promote lower body weight, blood pressure, and total
cholesterol.
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Our second finding highlights the role of socioeconomic and behavioural factors as being
important predictors of multimorbidity in those with pre-existing cardiometabolic disease.
Much of the research on multimorbidity has attempted to identify risk factors for multimor-
bidity, but not specifically the factors that lead to multimorbidity in those with a first cardio-
metabolic disease. Previous studies have shown socioeconomic factors [3,11] and behavioural
factors [16,19,20] to be associated with multimorbidity; however, some of these studies were
cross-sectional [3,11,19,30,31] and used self-reported measures of multimorbidity [19]. No
previous study to our knowledge has examined the role of risk factors in the progression from
1 disease to multimorbidity and death within a single analytic framework. The conventional
approach, demonstrated in our analyses using Cox regression (Table 2), suggests that the clus-
tering of clinical risk factors is important both for a first cardiometabolic disease and cardio-
metabolic multimorbidity. This is not the case when the role of risk factors was examined in
the risk of multimorbidity in those with 1 cardiometabolic disease, where clinical factors were
not associated with multimorbidity but both behavioural and socioeconomic risk scales pre-
dicted progression to multimorbidity, highlighting the need to understand the modifiers of
disease progression for effective prevention. Socioeconomic factors have long been known to
be major determinants of health [21], and continue to be seen to be important compared to
traditional risk factors [32]. Our results show them to be important predictors of multimorbid-
ity in persons with a first cardiometabolic condition even when the effects of clinical and beha-
vioural factors have been taken into account in the analysis.
The third finding highlights the key role of adverse midlife behavioural factors in risk of
mortality, in those without or with 1 or 2 or more cardiometabolic diseases. In those with car-
diometabolic multimorbidity, adverse behavioural factors were associated with as high as a
3.5-fold increased risk of death. Among the individual behavioural risk factors, our results
highlight the role of smoking in all 5 transitions from a healthy state to mortality. Previous
research has examined the risk of mortality in those with multimorbidity compared to disease-
free individuals; a recent paper found each of 3 cardiometabolic conditions to be associated
with a similar increased risk of mortality, and a combination of these diseases was associated
with a multiplicative mortality risk [4]. The multimorbidity–mortality association depends on
the specific chronic conditions used to characterise multimorbidity, whether they were self-
reported, and the duration of follow-up [11]. It is worth noting that few studies have examined
factors that modify the association of multimorbidity with mortality. There is some research
on interventions, mainly on the organisation of care delivery in multimorbid patients, but the
findings are inconclusive [12]. Our study is the first to our knowledge to examine the relative
importance of clinical, socioeconomic, and behavioural factors in modifying disease trajecto-
ries; these findings highlight the major role of behavioural factors. Previous findings have
highlighted the role of behavioural factors in mortality [33,34]; our findings show them to also
be critically important for secondary prevention.
The ageing of populations and reduced case fatality of major chronic conditions has led to
rapid increases in the prevalence of multimorbidity [3,10,11,30,31]; Scottish data on 1.7 mil-
lion adults registered with primary care providers show the prevalence of multimorbidity to
increase from 30% in those aged 45–64 to 65% in those aged 65–84 years [8]. However, the def-
inition of multimorbidity varies across studies. A simple count of all chronic conditions yields
prevalence rates of between 17% and 98%, depending on the conditions included in the list
[35]. A recent study used up to 40 conditions to define multimorbidity, and reported 42% of
persons to have 1 disease and 23% to have 2 or more diseases [8]. In our data, 30% had 1 cardi-
ometabolic disease, and 6% had cardiometabolic multimorbidity. Our use of a narrow set of
conditions that are leading causes of death or burden of disease allows the identification of
common etiopathogenic and prognostic factors. Better understanding of these patterns may
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lead to improvements in preventive actions to reduce prevalence and may also give rise to
new, more comprehensive approaches to the management of multimorbidity.
Our findings need to be considered in light of the study strengths and limitations. The
strengths of our study derive from the large sample size, the long follow-up to allow analyses on
clinically diagnosed incident diseases, and the availability of complete data on health outcomes.
Although a gold-standard definition of multimorbidity remains elusive, there is consensus on use
of clinically assessed rather than self-reported conditions [36]. A further strength is our analytic
strategy. To illustrate its value, we also report results of conventional survival analyses (Table 2),
which show clinical parameters to be important predictors of cardiometabolic multimorbidity.
However, they are less important in shaping temporal disease progression, as clinical parameters
were not associated with progression to multimorbidity in those with first cardiometabolic disease
or mortality in those with cardiometabolic multimorbidity. Thus, the large body of research on
risk and prognostic factors on individual disease outcomes may not be transferable to multimor-
bidity. We chose to study the role of risk factors at age 50 as risk factors assessed at older ages, in
particular health-related behaviours, are likely to be prone to reverse causation biases, and, for
clinical risk factors, there is evidence of significant tracking effects, defined as the longitudinal sta-
bility of the predictability of risk factors over time [37].
The primary limitation of our study is uncertain generalisability of findings as the results
from an occupational cohort from the UK such as the Whitehall II study are likely to apply
only to high-income countries with universal healthcare. A further limitation is that study par-
ticipants in occupational cohorts tend to be healthier than individuals in the general popula-
tion; however, this is an unlikely source of bias in risk factor–disease associations as we have
shown estimates from our study to be similar to those reported in general-population-based
studies [38]. As the Whitehall II study was designed to include a wide socioeconomic spec-
trum, with a 10-fold salary difference among the participants, the findings on socioeconomic
factors are likely to be generalisable [32]. Temporal changes in risk factor distributions over
the course of the study are unlikely to affect generalisability [39] as we estimated risk factor–
outcome associations rather than composite measures such as population attributable fractions
that also incorporate information on prevalence of risk factors. All risk factors were assessed at
age 50; changes in risk factor levels due to treatment or lifestyle modification were not exam-
ined in our study. As the data come from an observational study, the findings may be affected
by unobserved confounders. Finally, we chose to model 5 transitions rather than all possible
transitions between individual diseases and outcomes and between pairs of diseases in order to
simplify the analysis and interpretation of results. Transition A (healthy to first cardiometa-
bolic disease) is comparable to analysis of incident cardiometabolic disease using Cox regres-
sion; similar results from both approaches suggest that our estimates of the transitions
examined are robust and fit the data well.
I conclusion, multimorbidity is increasingly a challenge for patients, healthcare providers, and
the healthcare systems globally, but medical research and healthcare delivery continue to focus on
individual diseases. Our analysis of the natural history of cardiometabolic multimorbidity shows
clinical parameters to be key determinants of incidence of a first cardiometabolic disease but
socioeconomic and behavioural factors to determine progression to multimorbidity and beha-
vioural factors to be important in shaping risk of mortality. These results highlight the need for a
comprehensive approach to the primary and secondary prevention of cardiometabolic diseases.
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